Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 87

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 87
---
 interest income.

Note 13– Subsequent Events

On October 10, 2025,
the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors
(the “Purchasers”) pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement offering
(the “Private Placement”) an aggregate of 744,340 shares of common stock, and/or prefunded warrants in lieu thereof (the “Prefunded
Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,488,680 shares of common stock
at a per share exercise price of $6.32.  Each share of common stock (or Prefunded Warrant in lieu thereof) and accompanying Common
Warrants were sold at a combined purchase price of $6.57. The Private Placement closed on October 15, 2025.  

On October 23, 2025, the Company announced that
it had purchased 78,863.1 HYPE tokens with an estimated total value of approximately $3,000,000 as of October 21, 2025 to launch its Digital
Asset Treasury (“DAT”) strategy.

On October 29, 2025, the Company entered into
an At-The-Market Issuance Sales Agreement (the “ATM Agreement”) with Lucid Capital Markets, LLC, as sales agent (“Lucid”),
pursuant to which the Company may offer and sell, from time to time through Lucid, shares of its common stock, par value $0.0001 per share,
for aggregate gross proceeds of up to $1,750,000 (the “ATM Shares”).

Pursuant to the ATM Agreement, Lucid may sell
the ATM Shares in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities
Act, including sales made directly on or through the Nasdaq Capital Market. The Company and Lucid may also agree for the Company to sell
ATM Shares to Lucid as principal in negotiated transactions, at a purchase price agreed upon by Lucid and the Company. The offer and sale
of the ATM Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the issuance and sale of all of the ATM Shares
subject to the ATM Agreement, (b) the termination of the ATM Agreement by Lucid or the Company pursuant to the terms thereof, or